Alto Neuroscience Files 2025 Proxy Statement

Ticker: ANRO · Form: DEF 14A · Filed: 2025-04-01T00:00:00.000Z

Sentiment: neutral

Topics: proxy-statement, governance, annual-meeting

TL;DR

Alto Neuroscience filed its proxy statement for the annual meeting - shareholders vote on directors & pay.

AI Summary

Alto Neuroscience, Inc. filed its definitive proxy statement on April 1, 2025, for its annual meeting. The filing covers the fiscal year ending December 31, 2024, and details matters to be voted on by shareholders, including the election of directors and executive compensation.

Why It Matters

This filing provides shareholders with crucial information regarding company governance, director nominations, and executive compensation, enabling informed voting decisions.

Risk Assessment

Risk Level: low — This is a routine annual filing (DEF 14A) and does not contain new material financial or operational information that would inherently increase risk.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a DEF 14A filing?

A DEF 14A filing, or definitive proxy statement, is used by companies to solicit shareholder votes on important matters such as the election of directors, executive compensation, and other corporate actions.

When does the fiscal year covered by this proxy statement end?

The fiscal year covered by this proxy statement ends on December 31, 2024.

What is the filing date of this proxy statement?

This definitive proxy statement was filed on April 1, 2025.

What is Alto Neuroscience, Inc.'s Standard Industrial Classification code?

Alto Neuroscience, Inc.'s Standard Industrial Classification code is 2834, which corresponds to Pharmaceutical Preparations.

Where is Alto Neuroscience, Inc. headquartered?

Alto Neuroscience, Inc. is headquartered at 650 Castro Street, Suite 450, Mountain View, CA 94041.

From the Filing

0001193125-25-070446.txt : 20250401 0001193125-25-070446.hdr.sgml : 20250401 20250401161712 ACCESSION NUMBER: 0001193125-25-070446 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250513 FILED AS OF DATE: 20250401 DATE AS OF CHANGE: 20250401 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alto Neuroscience, Inc. CENTRAL INDEX KEY: 0001999480 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 834210124 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-41944 FILM NUMBER: 25799888 BUSINESS ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 BUSINESS PHONE: 773-255-5012 MAIL ADDRESS: STREET 1: 650 CASTRO STREET, SUITE 450 CITY: MOUNTAIN VIEW STATE: CA ZIP: 94041 DEF 14A 1 d936566ddef14a.htm DEF 14A DEF 14A Table of Contents DEF 14A false 0001999480 0001999480 2024-01-01 2024-12-31     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )     Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box:   ☐ Preliminary Proxy Statement   ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))   ☒ Definitive Proxy Statement   ☐ Definitive Additional Materials   ☐ Soliciting Material under § 240.14a-12 ALTO NEUROSCIENCE, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply):   ☒ No fee required   ☐ Fee paid previously with preliminary materials   ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11       Table of Contents ALTO NEUROSCIENCE, INC. 650 Castro Street, Suite 450 Mountain View, California 94041 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS To Be Held On May 13, 2025 Dear Alto Neuroscience, Inc. Stockholder: You are cordially invited to attend the 2025 annual meeting of stockholders (the “Annual Meeting”) of Alto Neuroscience, Inc., a Delaware corporation (“we” or “us,” or the “Company”), which will be held on Tuesday, May 13, 2025 at 8:30 a.m. Eastern Time. The Annual Meeting will be virtual, held via live webcast, through which you can listen to the meeting, submit questions, and vote online. There is no physical location for the Annual Meeting. The Annual Meeting will be held for the following purposes:     1. To elect the Board of Director’s nominee named in the accompanying proxy statement (“Proxy Statement”) to serve as a Class I director until the 2028 Annual Meeting of Stockholders;     2. To ratify the Audit Committee of the Company’s Board of Directors’ selection of Deloitte & Touche LLP (“Deloitte”) as our independent registered public accounting firm for the fiscal year ending December 31, 2025; and     3. To conduct any other business properly brought before the Annual Meeting. These items of business are more fully described in the Proxy Statement accompanying this Notice. The Annual Meeting can be attended by visiting www.virtualshareholdermeeting.com/ANRO2025 and entering your 16-digit Control Number included in your Notice of Internet Availability of Proxy Materials, proxy card or voting instruction form sent to you. You may log-in to the Annual Meeting beginning at 8:15 a.m. Eastern Time, on Tuesday, May 13, 2025. Please refer to the additional logistical details and recommendations in the accompanying Proxy Statement. The record

View on Read The Filing